Orion (ORNBV) Q3 2024 earnings summary

Executive summary

• Net sales for January–September 2024 rose 27.6% year-over-year to EUR 1,108.0 million, with operating profit up 77.9% to EUR 323.8 million, driven by milestone payments and strong growth in Nubeqa®, Easyhaler®, and Animal Health.

• EUR 130 million in milestone payments recognized, including EUR 70 million from Nubeqa® and EUR 60 million from the MSD agreement transition to a license model.

• Excluding major milestones, net sales increased 16.6% and operating profit 27.5% year-over-year, with robust cash flow from operating activities.

• Nubeqa® became the first blockbuster, surpassing EUR 1 billion in in-market sales, and remains a key growth driver alongside Easyhaler®, Animal Health, and generics.

• Key R&D events included the termination of the ODM-111 program and discontinuation of ganaxolone clinical development after a failed phase III trial, while the ARANOTE trial for darolutamide met its primary endpoint.

Financial highlights

• Q3 2024 net sales increased 56.5% year-over-year to EUR 471.3 million, with operating profit more than doubling to EUR 202.0 million, both boosted by milestone payments.

• Excluding milestones, underlying business growth was 25.9% in Q3; net operating profit up EUR 22 million year-over-year.

• Operating profit margin for January–September 2024 was 29.2%, up from 21.0% a year earlier.

• Cash flow from operating activities per share reached EUR 1.46, more than doubling from EUR 0.50 a year ago.

• R&D expenses increased 29.7% to EUR 117.1 million, representing 10.6% of net sales.

Outlook and guidance

• 2024 net sales expected at EUR 1,470–1,510 million and operating profit at EUR 370–400 million, both upgraded during the period.

• EBIT guidance includes known write-downs: EUR 17.5 million for ODM-111 and up to EUR 25 million for ganaxolone, with final ganaxolone write-down under assessment.

• Long-term EBIT and sales growth targets remain unchanged despite R&D reallocations.

• Outlook includes EUR 70 million Nubeqa® milestone and EUR 60 million from MSD contract conversion; no other material one-offs included.